Siemens Healthineers will invest around $300 million in its Walpole laboratory diagnostics manufacturing and research and development (R&D) facility. The investment extends over four years.
“The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint in the United States, the largest healthcare market in the world,” said Bernd Montag, CEO of Siemens Healthineers.
“The laboratory instruments and reagents developed and manufactured at the Siemens Healthineers Walpole facility impact patients and healthcare providers across the globe.”
The Walpole facility currently employs over 700 employees and is the main manufacturing facility for assays that run on the ADVIA Centaur family of immunoassay instruments, and for consumables for the company's molecular and blood gas testing instruments.
The facility will also manufacture assays to run on the immunoassay module of the Atellica Solution, which is currently under FDA review. R&D efforts at the site bring new tests to the diagnostics market to help physicians diagnose and treat disease.
Franz Walt, president of laboratory diagnostics at Siemens Healthineers, said: “With a 37-year history of manufacturing products in Walpole, we saw an opportunity to leverage the local talent in the community to further our growth and expansion plans.”
Siemens Healthineers, US, Healthcare, Risk management, Diagnostics, Walpole, Bernd Montag, Franz Walt